Now showing items 1-7 of 7
Giardiasis : with emphasis on treatment and post-infectious manifestations
(The University of Bergen, 2010-05-21)
Severity of Giardia infection associated with post-infectious fatigue and abdominal symptoms two years after
(BioMed Central, 2009-12-15)
Background: A high rate of post-infectious fatigue and abdominal symptoms two years after a waterborne outbreak of giardiasis in Bergen, Norway in 2004 has previously been reported. The aim of this report was to identify ...
Immunophenotyping in post-giardiasis functional gastrointestinal disease and chronic fatigue syndrome
(BioMed Central, 2012-10-14)
Background: A Giardia outbreak was associated with development of post-infectious functional gastrointestinal disorders (PI-FGID) and chronic fatigue syndrome (PI-CFS). Markers of immune dysfunction have given conflicting ...
A novel, single-amplification PCR targeting mitochondrial genome highly sensitive and specific in diagnosing malaria among returned travellers in Bergen, Norway
(BioMed Central, 2013-01-22)
Background: Nested PCR is a commonly used technique in diagnosis of malaria owing to its high sensitivity and specificity. However, it is time-consuming, open to considerable risk of contamination and has low cost-efficiency. ...
PNPLA 3 I148M genetic variant associates with insulin resistance and baseline viral load in HCV genotype 2 but not in genotype 3 infection
(BioMed Central, 2012-09-14)
Background: Hepatic steatosis in HCV patients has been postulated as a risk factor associated with a higher frequency of fibrosis and cirrhosis. A single genetic variant, PNPLA3 I148M, has been widely associated with ...
Fever in the tropics: aetiology and case-fatality - a prospective observational study in a tertiary care hospital in South India
(BioMed Central, 2013-07-30)
Background: The objective of this study was to describe aetiology and case fatality of fever among inpatients in a tertiary care hospital in South India.Methods: This was an observational, prospective study conducted in ...
Impact of Obesity on the Bioavailability of Peginterferon-α2a and Ribavirin and Treatment Outcome for Chronic Hepatitis C Genotype 2 or 3
(Public Library of Science, 2012-05-24)
Background and Aims: Having a body mass index above or equal to 30 kg/m2 in conjunction with chronic hepatitis C virus infection is associated with non-responsiveness to treatment with interferon and ribavirin, but details ...